<DOC>
	<DOCNO>NCT00141102</DOCNO>
	<brief_summary>To determine whether celecoxib superior combine therapy diclofenac omeprazole incidence clinically significant upper and/or lower gastrointestinal ( GI ) event high GI risk subject osteoarthritis and/or rheumatoid arthritis .</brief_summary>
	<brief_title>Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal ( GI ) Safety In High GI Risk Patients With Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Subjects clinical diagnosis OA RA expect require regular antiinflammatory therapy arthritis symptom management Subjects must age 60 year old without history gastroduodenal ( GD ) ulceration ; age 18 year old document evidence GD ulceration 90 day prior screen visit Active GD ulceration GD ulceration within 90 day screen visit . Concomitant use low dose aspirin Previous MI , stroke significant vascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>GI event high risk GI arthritis patient</keyword>
</DOC>